Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

El tratamiento del cáncer de mama ha terminado, pero el sueño no ha regresado: se probarán aplicaciones de teléfonos inteligentes en 747 mujeres
Escuchar un jadeo no es suficiente: por qué un nuevo estudio añade vídeo de teléfonos inteligentes a las llamadas de emergencia
Lo que puede revelar una exhalación: se probará una nueva prueba en 1.000 pacientes con sospecha de cáncer de estómago e intestino
Antes de los primeros problemas de memoria: Roche probará un fármaco en personas con biomarcadores de Alzheimer
A Diaper Photo Could Help Spot Liver Disease in Babies: UK Tests AI
El tumor permanece después del tratamiento: se probará una nueva combinación en 1.000 pacientes con cáncer de mama agresivo
Tratamiento del VIH sin pastillas diarias: Gilead probará un nuevo régimen de acción prolongada en dos ensayos de fase 3

Próximos ensayos clínicos

Clinical Research Jobs

More jobs

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

Suscribir